Placebo olaparib

Phase 3

AstraZeneca

Placebo olaparib is one of 5 therapeutic programs targeting Advanced Ovarian Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Ovarian CancerActive, not recruiting

Advanced Ovarian CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Advanced Ovarian Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

1 2

Lynparza

AstraZeneca

Phase 3

1 3

Avastin

BBio-Thera Solutions

Phase 3

1 4

Paraplatin

AAvyxa

Phase 3

1 5

Placebo olaparib

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Advanced Ovarian Cancer

NCT03737643

Clinical

Trials by Indication[1]

Advanced Ovarian Cancer1 trial

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT03737643·1,407 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo olaparib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo olaparib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AstraZeneca

Placebo olaparib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Advanced Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News